Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials

References

• Shaw JESR, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Ley SH, Hu FBJNRE. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017;14(2):88–98.
   PubMed Web of Science ®Google Scholar
• Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281.
   PubMed Web of Science ®Google Scholar
• Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585.
   PubMed Web of Science ®Google Scholar
• Rana D, Kumar A. Is there a role for sodium orthovanadate in the treatment of diabetes? Curr Diabetes Rev. 2019;15(4):284–287.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectr. 2012;25(3):154–171.
   Google Scholar
• Dendup T, Feng X, Clingan S, et al. Environmental risk factors for developing type 2 diabetes mellitus: a systematic review. Int J Environ Res Public Health. 2018;15(1):78.10.
   PubMed Web of Science ®Google Scholar
• Fallahzadeh H, Ostovarfar M, Lotfi MH. Population attributable risk of risk factors for type 2 diabetes; Bayesian methods. Diabetes Metab Syndr. 2019;13(2):1365–1368.
   PubMed Web of Science ®Google Scholar
• Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33(3):501–506.
   PubMed Web of Science ®Google Scholar
• Eurich DT, Simpson SH, Majumdar SR, et al. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy. 2005;25(6):810–816.
   PubMed Web of Science ®Google Scholar
• Administration UFaD. Type 2 diabetes mellitus and invokana: an FDA approved drug. Curr Diabetes Rev. 2013 March 29;9(6):478–490.
   PubMedGoogle Scholar
• Chao EC, Henry RR. SGLT2 inhibition — a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9:551.
   PubMed Web of Science ®Google Scholar
• Miller BR, Nguyen H, Hu CJ, et al. New and emerging drugs and targets for type 2 diabetes: reviewing the evidence. Am Health Drug Benefits. 2014;7(8):452–463.
   PubMedGoogle Scholar
• Akhtar N. Type 2 diabetes mellitus and Invokana: an FDA approved drug. Curr Diabetes Rev. 2013;9(6):478–490.
   PubMedGoogle Scholar
• Ko SH, Hur KY, Rhee SY, et al. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Korean J Internal Medi. 2017;41(5):337–348.
   Google Scholar
• Poole RM, Dungo RT. Ipragliflozin: First Global Approval. Drugs. 2014;74(5):611–617.
   PubMed Web of Science ®Google Scholar
• Hedrington MS, Davis SN. Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015;11(4):613–623.
   PubMed Web of Science ®Google Scholar
• Veltkamp SA, Kadokura T, Krauwinkel WJJ, et al. Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig. 2011;31(12):839–851.
   PubMed Web of Science ®Google Scholar
• Shestakova MV, Wilding JP, Wilpshaar W, et al. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;146:240–250.
   PubMed Web of Science ®Google Scholar
• Ohkura T. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes. 2015;6(1):136–144.
   PubMed Web of Science ®Google Scholar
• Ishihara H, Yamaguchi S, Nakao I, et al. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study. Diabetol Int. 2019;10(1):37–50.
   PubMed Web of Science ®Google Scholar
• Han K-A, Chon S, Chung CH, et al. Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial. Diabetes Obes Metab. 2018;20(10):2408–2415.
   PubMed Web of Science ®Google Scholar
• Terauchi Y, Yokote K, Nakamura I, et al. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): interim results of a post-marketing surveillance study. Expert Opin Pharmacother. 2016;17(4):463–471.
   PubMed Web of Science ®Google Scholar
• Wu JHY, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411–419.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P)2015 statement. Syst Rev. 2015;4(1):1.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Lu CH, Min KW, Chuang LM, et al. Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial. J Diabetes Investig. 2016;7(3):366–373.
   PubMed Web of Science ®Google Scholar
• Kashiwagi A, Kazuta K, Goto K, et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double‐blind, placebo‐controlled study. Diabetes Obesity Metab. 2015;17(3):304–308.
   PubMed Web of Science ®Google Scholar
• Wilding J, Ferrannini E, Fonseca V, et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose‐finding study. Diabetes Obesity Metab. 2013;15(5):403–409.
   PubMed Web of Science ®Google Scholar
• Veltkamp SA, van Dijk J, Collins C, et al. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin Ther. 2012;34(8):1761–1771.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration\”s tool for assessing risk of bias in randomised trials. Bmj Br Med J. 2011;343(7829):889–893.
   Google Scholar
• Terasaki M, Hiromura M, Mori Y, et al. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLoS One. 2015;10(11):e0143396.
   PubMed Web of Science ®Google Scholar
• Takakura S, Toyoshi T, Hayashizaki Y, et al. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. Life Sci. 2016;147:125–131.
   PubMed Web of Science ®Google Scholar
• Kashiwagi A, Kazuta K, Takinami Y, et al. Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. Diabetol Int. 2015;6(1):8–18.
   Web of Science ®Google Scholar
• Kadokura T, Akiyama N, Kashiwagi A, et al. Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. Diabetes Res Clin Pract. 2014;106(1):50–56.
   PubMed Web of Science ®Google Scholar
• Bailey C. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32(2):63–71.
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Barnett AH, Bailey C. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1(2):140–151.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88.
   PubMed Web of Science ®Google Scholar
• Kashiwagi A, Yoshida S, Nakamura I, et al. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. . Diabetes Res Clin Pract. 2018;146(4):240–250.
   Google Scholar
• Elgebaly A, Abdelazeim N, Abdelazeim B, et al. Tolerability and efficacy of ipragliflozin in the management of inadequately controlled type 2 diabetes mellitus: a systematic review and meta-analysis. Exp Clin Endocrinol Diabetes. 2018. DOI:10.1055/a-0579-7860
   PubMedGoogle Scholar
• Schork A, Saynisch J, Vosseler A, et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol. 2019;18(1):46.
   PubMedGoogle Scholar
• Lee SJCPC. Update on SGLT2 inhibitors-new data released at the American Diabetes Association. Crit Pathw Cardiol. 2017;16(3):93–95.
   PubMedGoogle Scholar
• Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136(17):1643–1658.
   PubMed Web of Science ®Google Scholar
• Pinto LC, Rados DV, Remonti LR, et al. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetol Metab Syndr. 2015;7(1):A58.
   PubMedGoogle Scholar
• Fox CS, Pencina MJ, Wilson PW, et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care. 2008;31(8):1582–1584.
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136(17):1643–1658.
   PubMed Web of Science ®Google Scholar
• Oliva RVBGL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soci Hypertens. 2014;8(5):330–339.
   PubMed Web of Science ®Google Scholar
• Müller-Wieland D, Kellerer M, Cypryk K, et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obesity Metab. 2018;20(11):2598–2607.
   PubMed Web of Science ®Google Scholar
• Ting Y, Min L, Lingyue M, et al. Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis. Eur J Clin Pharmacol. 2015;71(11):1325–1332.
   PubMed Web of Science ®Google Scholar
• Zhong X, Lai D, Ye Y, et al. Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2016;72(6):655–663.
   PubMed Web of Science ®Google Scholar
• Saito‐Sasaki N, Sawada Y, Nishio D, et al. First case of drug eruption due to ipragliflozin: Case report and review of the literature. Australas J Dermatol. 2017;58(3):236–238.
   PubMed Web of Science ®Google Scholar
• Yabe D, Nishikino R, Kaneko M, et al. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opinion on Drug Safety. 2015;14(6):795–800.
   Google Scholar
• Sakaeda T, Kobuchi S, Yoshioka R, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018;15(9):937.
   PubMed Web of Science ®Google Scholar
• Hedrington MS, Davis SN. %J expert opinion on drug metabolism, toxicology. ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015;11(4):613–623.
   PubMed Web of Science ®Google Scholar
• Li J, Gong Y, Li C, et al. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: a meta-analysis. Medicine. 2017;96:27.
   Web of Science ®Google Scholar
• Inoue T, Takemura M, Fushimi N, et al. Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation. Eur J Pharmacol. 2017;806:25–31.
   PubMed Web of Science ®Google Scholar
• Elgebaly A, Abdelazeim N, Abdelazeim B, et al. Tolerability and efficacy of ipragliflozin in the management of inadequately controlled type 2 diabetes mellitus: a systematic review and meta-analysis. 2018;(EFirst). doi:10.1055/a–0579–7860
   Google Scholar
• Pawe K, Alicja M, Sylwia O, et al. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014;30(4):269–283.
   PubMed Web of Science ®Google Scholar
• Puckrin R, Saltiel M-P, Reynier P, et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):503–514.
   PubMed Web of Science ®Google Scholar
• And CFDE. Drug Safety and availability - FDA Drug safety communication: FDA warns of rare but serious hypersensitivity reactions with certain over-the-counter topical acne products. Drugs. 2016.
   Google Scholar
• Tang H, Li D, Wang T, et al. Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2016;39(8):e123.
   PubMed Web of Science ®Google Scholar
• Singh M, Sharma R, Kumar A. Safety of SGLT2 inhibitors in patients with diabetes mellitus. Curr Drug Saf. 2019;14(2):87–93.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia. 2017;60(8):1–5.
   PubMed Web of Science ®Google Scholar
• Perry RJ, Rabin-Court A, Song JD, et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun. 2019;10(1):548.
   PubMedGoogle Scholar
• Singh M, Kumar A. Risks associated with SGLT2 inhibitors: an overview. Curr Drug Saf. 2018;13(2). DOI:10.2174/1574886313666180226103408
   Web of Science ®Google Scholar
• DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38(3):384–393.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Shestakova MV, Trubitsyna NP, et al. Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. Diabetes Res Clin Pract. 2016;112:50–56.
   PubMed Web of Science ®Google Scholar